Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Novavax AB
AB
Active
Org 5565494019
Kungsgatan 109, 753 18
Uppsala
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 1997 · 28 years old
173 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Novavax AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
2.0B
1.5B
1.0B
0.5B
-0.0B
2020: 0.4B
0.4B
2020
2021: 1.0B (+148% vs 2020)
1.0B
+148%
2021
2022: 1.6B (+60% vs 2021)
1.6B
+60%
2022
2023: 0.8B (-48% vs 2022)
0.8B
-48%
2023
2024: 0.5B (-36% vs 2023)
0.5B
-36%
2024
EBITDA
SEK millions
721M
462M
202M
-57M
-316M
2020: -12M
-12M
2020
2021: -112M (-833% vs 2020)
-112M
-833%
2021
2022: 517M (+562% vs 2021)
517M
+562%
2022
2023: 200M (-61% vs 2022)
200M
-61%
2023
2024: 105M (-47% vs 2023)
105M
-47%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
524 647
820 346
1 570 987
980 891
395 176
Staff expenses
—
—
—
—
—
EBITDA
104 765
200 182
517 253
−111 547
−11 698
Depreciation & amort.
—
—
—
—
—
EBIT
104 765
200 182
517 253
−111 547
−11 698
Net financials
155 510
−601 390
−680 903
−379 103
−195 722
Profit before tax
260 275
194 900
518 188
−111 565
−11 703
Tax
−54 471
−5 605
417
−0
−0
Net profit
205 804
189 295
518 605
−111 565
−11 703
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
2 654 994
3 615 737
3 747 809
3 593 711
2 573 297
Equity
2 517 637
2 296 795
2 086 642
1 513 380
1 311 696
Long-term debt
0
0
0
0
0
Short-term debt
131 064
1 318 942
1 661 167
2 080 331
1 261 601
Total debt
131 064
1 318 942
1 661 167
2 080 331
1 261 601
Financial ratios
5-year trend
EBITDA margin
20,0 %
This company
15,8 %
Market median
This company
Market median
27% above market
2020
2024
Equity ratio
94,8 %
This company
38,2 %
Market median
This company
Market median
148% above market
2020
2024
Return on equity
8,2 %
This company
18,4 %
Market median
This company
Market median
55% below market
2020
2024
Net profit margin
39,2 %
This company
8,1 %
Market median
This company
Market median
384% above market
2020
2024
Asset turnover
0,20×
This company
1,12×
Market median
This company
Market median
82% below market
2020
2024
Debt / equity
0,05×
This company
0,62×
Market median
This company
Market median
92% below market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Novavax AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
